Drugs / CD4+ T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02210104 | Dec 2016 → Dec 2019 | melanoma, sarcoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD4+ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02210104 ↗ |
| Modality | Cell therapy | “Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells” NCT02210104 ↗ |
| Route | Intravenous | “you will receive the CD4+T cells by vein over about 30-60 minutes” NCT02210104 ↗ |